Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... orphan diseases were 15.73 bln rubles per year (6.36 bln rubles for children and 9.37 bln rubles ..."
 
Vol 12, No 4 (2019) Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation Abstract  similar documents
A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev
"... the costs of drugs for solid tumors at the 352.2 million rubles for 5 years (baseline scenario), 69 ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal ..."
 
Vol 7, No 4 (2014) APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES Abstract  similar documents
V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova
"... financing of rare disease drugs remains a serious problem for both foreign countries and our ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov
"... combined drug is cost saving alternative that annually requires 22,000 rubles per patient, which is 2 ..."
 
Vol 12, No 3 (2019) Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings Abstract  similar documents
O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev
"... ) analysis was used to evaluate the actual drug consumption based on the defined daily dose; DU90% (Drug ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... of the Russian Federation in three scenarios: Lacosamide as concomitant drug to standard therapy in comparison ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..."
 
Vol 10, No 1 (2017) RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES OF FINANCE, AND GUIDELINES FOR CREATION Abstract  similar documents
M. V. Sura
"... and sources of finance pertaining to the restrictive lists of drugs, which play a substantial role in the drug ..."
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... the reference drug combinations (8 vs 18 days and 75% vs 34.8%, respectively, p=0.031). The cost of treatment ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... obstructive bronchitis in children. The original drug Augmentin (Smithkline Beecham Pharmaceuticals ..."
 
Vol 8, No 4 (2015) ABC-, VEN- AND FREQUENCY ANALYSIS OF TREATMENT OF ATRIAL FIBRILLATION IN OUTCOME PATIENTS Abstract  similar documents
A. N. Korobeynikova, S. V. Malchikova
"... studies allow to evaluate the quality of drug therapy for atrial fibrillation, find rational drug usage ..."
 
Vol 10, No 2 (2017) CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... in medical costs from 873.00 rubles to 1515.39 rubles, and to a decrease in the average number ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... medication reached 4,888 rubles, which is 13% less than that with the mono-component drug. If the current ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... Abstract: the pharmacoeconomic study compared the standard drug therapy (vitamin D ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION Abstract  similar documents
A. Yu. Kulikov, I. Yu. Zinchuk
"... Based on meta-analysis dates found, that the effectiveness of neuroprotective drugs and placebo ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... of drugs from the list of vital and essential drugs (VED), the size of the maximal wholesale mark-ups ..."
 
Vol 10, No 3 (2017) Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia Abstract  similar documents
E. V. Ivanova, K. Z. Bachtiyarova
"... 428,222,026.35 rubles per year, mostly due to direct medical costs; of those, almost 50% is spent ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... ) new practice where lenvatinib is used in 6.25% patients. Costs of drugs, visits to oncologist ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... between the drugs in terms of clinical efficacy and safety and this hypothesis is grounded on the results ..."
 
Vol 10, No 2 (2017) COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
"... The recently introduced novel drug combinations for the treatment of COPD are based on long-acting ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... with the severity of the injury 31 points and made 11 000 and 5600 rubles. respectively. The cost of treating ..."
 
Vol 12, No 2 (2019) Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers Abstract  similar documents
E. V. Radchenko, A. S. Kolbin
"... disability) was 510.6 billion rubles. The difference between the smokers and the equal-sized non-smoking ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... ®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... .14 rubles, respectively). The cost per averted case of NE was 21 115 rubles within 35 days that is less than ..."
 
Vol 8, No 2 (2015) CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER Abstract  similar documents
Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov
"... of treatment five subclavian catheters necessary to spend 227.25 mln. rubles. And the implantations of venous ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation Abstract  similar documents
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
"... the competitors. To prevent asthma exacerbations by omalizumab requires 463 805 rubles, which is 24.80% less than ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... ,704.90 rubles. and 145,473.70 rubles, respectively, while in group 3, the cost was higher – 167,443,60 rubles (p ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... ,878.21 rubles, and the cost of one additionally saved QALY – 365,060.31 rubles. Conclusion. The WTPT ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group ..."
 
Vol 10, No 1 (2017) PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM Abstract  similar documents
N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
"... Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y ..."
 
Vol 11, No 1 (2018) Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) Abstract  similar documents
O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov
"... of moderate CAP were: 10.5 days and 731.65 rubles for ceftriaxone;  9.1 days and 1353.00 rubles ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... insulin for the model population of 1,000 patients was 22.5 million rubles. If the use of ready-made ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... with vector-borne infectious diseases comprised 909 million rubles in prices of 2011; most of the value ..."
 
Vol 7, No 3 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA Abstract  similar documents
A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova
"... .2%. Middle cover price of case report was 252,294 rubles. In average oxaliplatin therapy was effective in 83 ..."
 
Vol 8, No 4 (2015) HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS Abstract  similar documents
N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova
"... healthcare spending inefficient, which equals to real 269-435 billion rubles of inefficient spending annually.  ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... with Revlimid in Russia was conducted. It has shown, that application of lenalidomide as a drug of choice ..."
 
Vol 11, No 3 (2018) What is the role of antineoplastic drug safety in reimbursement decision making? Abstract  similar documents
A. S. Kolbin, A. A. Kurylev
"... Rationale. From 2014 to 2017, the portion of antineoplastic drugs dossiers submitted ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... part we calculated ICER for BV vs standard treatment based on drugs costs only and compared ..."
 
Vol 8, No 4 (2015) PLANNING OF EXTENT AND FINANCIAL EXPENSES FOR DELIVERY OF HEALTH CARE IN HOSPITALS AT THE FEDERAL AND REGIONAL LEVELS Abstract  similar documents
M. V. Sura
"... per year; the norm of financial expenses was 63 743,8 rubles and 22 233,1 rubles per one case ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... costs included drugs and medical resources (hospitalization, emergency care costs, visits to physician ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... .9 billion rubles (42.2 million EUR). According to the generated modelling, the pneumococcal (PPSV23 ..."
 
Vol 9, No 1 (2016) MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 Abstract  similar documents
A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
"... Background: In 2014 we firstly analyzed the formalized system (points and expert opinions) of drug ..."
 
Vol 7, No 1 (2014) PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE Abstract  similar documents
S. A. Rachina, R. S. Kozlov, Yu. A. Belkova
"... the use of and the effects of drugs in the whole population or in large groups of people in order ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
"... cancer in various regions of the Russian Federation in the framework of state programs of drug provision ..."
 
Vol 12, No 2 (2019) Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available Abstract  similar documents
F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev
"... trends in the general picture of drug prices and consumption. In the present study, we analyze ..."
 
1 - 50 of 133 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)